Phase 2 N=16 D-cycloserine and Treatment of Feeding Disorders
Feeding Disorders · Specific Phobia
Primary: Rapid Swallowing — 18.6; 14.3 percentage of bites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease · Lung Disease
Primary: Absolute Monocyte Count in BAL Post-LPS Challenge — 398; 514.4 x10^4 cells/mL
Phase 2 N=63 AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
Chronic Obstructive Pulmonary Disease · Lung Disease
Primary: Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes — 0; 0 Participants
Phase 2 N=45 Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria — 71; 82 percentage of…
Phase 2 N=167 A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Hepatitis C
Primary: Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT) — 19; 14; 26; 13 Participants
Phase 2 N=105 Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Leukemia · Lymphoma
Primary: Complete Response Rate — 83 percentage of participants
Phase 2 N=21 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Marijuana Abuse
Primary: Marijuana Use — 2.5; 3.9 Reported uses per day
Phase 2 N=76 A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion — 29.7; 17.9 percentage of participants — p=0.238
Phase 2 N=8 Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…
Phase 2 N=22 This is a Study to Determine the Antidepressant Effects of AZD6765
Treatment Resistant Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — 26.881; 28.618; 25.381; 29.718 Units on a scale
Phase 2 N=31 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
Psoriasis-Type Psoriasis · Plaque-Type Psoriasis
Primary: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase — 25; 13; 3; 1 participants
Phase 2 N=55 Transdermal Electroacupuncture for Opioid Detoxification
Opioid Dependency
Primary: Percent of Participants Using Drugs — 35; 77 percent
Phase 2 N=99 Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
HIV-1 Infection
Primary: Absolute Change in Relative FMD (%) — 0.60; 0.50 % FMD — p=0.28
Phase 2 N=20 Kudzu Treatment for Alcohol Abuse
Alcohol Consumption
Primary: Drinking Behaviors — 3.4; 1.9 beers consumed
Phase 2 N=45 Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) · Adult Acute Myeloblastic Leukemia
Primary: Compete Remission (CR) Rate — 28 percentage of subjects